Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410124 | 0.93 | IDO1 (0.31) | IDO1AGXTCA1 | |
| SCHEMBL4563246 | 0.93 | IDO1 (0.31) | IDO1AGXTCA1 | |
| SCHEMBL28045261 | 0.83 | IDO1 (0.43) | IDO1AGXTTSHRALDH1A1LMNA | |
| SCHEMBL5215859 | 0.76 | PPARA (0.34) | PPARAALDH1A1LMNA | |
| SCHEMBL15892824 | 0.72 | MAPT (0.34) | HTT | |
| SCHEMBL7565329 | 0.72 | AGXT (0.48) | IDO1AGXTCA1 | |
| SCHEMBL1315036 | 0.69 | IDO1 (0.46) | IDO1AGXTTSHRALDH1A1LMNA | |
| SCHEMBL6111479 | 0.67 | TSHR (0.48) | IDO1AGXTCA1TSHRALDH1A1 | |
| SCHEMBL29291372 | 0.67 | TSHR (0.46) | IDO1AGXTCA1TSHRALDH1A1 | |
| SCHEMBL31084123 | 0.67 | IDO1 (0.33) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642644-B2 | Ophthamological drugs | DUKE UNIVERSITY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20090318542-A1 | OPHTHAMOLOGICAL DRUGS | DUKE UNIVERSITY | 2009-12-24 | — | — | US | disclosed |
| EP-1812017-A2 | OPHTHAMOLOGICAL DRUGS | Duke University (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060135609-A1 | Ophthamological drugs | DUKE UNIVERSITY (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006047466-A2 | OPHTHAMOLOGICAL DRUGS | DUKE UNIVERSITY (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135609-A1 | Ophthamological drugs | QDPR, PTGIR, PDE6C | IDO1 98/4885AGXT 3360/4885CA1 1914/4885 |
| US-20090318542-A1 | OPHTHAMOLOGICAL DRUGS | QDPR, PTGIR, PDE6C | IDO1 109/4885AGXT 3079/4885CA1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.